2009
DOI: 10.1007/s00464-009-0575-3
|View full text |Cite
|
Sign up to set email alerts
|

Minimally invasive colon resection for malignant colonic conditions is associated with a transient early increase in plasma sVEGFR1 and a decrease in sVEGFR2 levels after surgery

Abstract: sVEGFR2 values decreased and sVEGFR1 levels increased early after MICR; sVEGFR2 changes dominate due to their much larger magnitude. The net result is less plasma VEGF bound by soluble receptors and more plasma VEGF available to bind to ECs early after surgery.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
6
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(8 citation statements)
references
References 44 publications
2
6
0
Order By: Relevance
“…Median plasma PlGF in other cancer forms range from 19 pg/mL in rectal cancer [61] to 35.5 pg/mL in renal cell carcinoma [16], which is in accordance with our findings. We found the median plasma sVEGFR2 level to be 9430 pg/mL, which is in accordance with what was found in plasma from patients with renal cell carcinoma (median 9554 pg/mL) [16] and in plasma from colorectal cancer patients (mean 7584 pg/mL) [57]. Median sEGFR in serum from colorectal cancer patients was in a previous study 47.9 ng/mL [62], 52.8 ng/mL in serum from patients with breast cancer [34], 25.3 ng/mL in serum from patients with NSCLC [39], and 36.4 ng/mL in serum from healthy individuals [39], which is similar to our findings.…”
Section: Discussionsupporting
confidence: 90%
“…Median plasma PlGF in other cancer forms range from 19 pg/mL in rectal cancer [61] to 35.5 pg/mL in renal cell carcinoma [16], which is in accordance with our findings. We found the median plasma sVEGFR2 level to be 9430 pg/mL, which is in accordance with what was found in plasma from patients with renal cell carcinoma (median 9554 pg/mL) [16] and in plasma from colorectal cancer patients (mean 7584 pg/mL) [57]. Median sEGFR in serum from colorectal cancer patients was in a previous study 47.9 ng/mL [62], 52.8 ng/mL in serum from patients with breast cancer [34], 25.3 ng/mL in serum from patients with NSCLC [39], and 36.4 ng/mL in serum from healthy individuals [39], which is similar to our findings.…”
Section: Discussionsupporting
confidence: 90%
“…But the presence of extracelluar VEGF-binding domains in sVEGRF1 and sVEGRF2 ensure that they can sequester plasma VEGF and decrease the level of free VEGF, thus decreasing pro-angiogenic effect on vascular endothelial cell. sVEGFR1 and sVEGFR2 are considered as negative regulators in the process of angiogenesis by decreasing the availability of VEGF to the endothelial cells (9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%
“…These changes in sVEGFR have also been observed in patients following major colorectal surgery [11]. sVEGFR are soluble variants of VEGF-receptors (VEGFRs) that are produced by the receptors alternative splicing.…”
Section: Discussionmentioning
confidence: 97%
“…The soluble forms have a high affinity for VEGF and sequester free VEGF 165 in the blood. Since sVEGFR does not have signaling capabilities, sVEGFR1 and sVEGFR2 competitively inhibit VEGF-mediated activation of endothelial cell-bound receptors, and, therefore, to a certain extent discourages angiogenesis [11]. Interestingly, breast and colorectal cancers can express sVEGFR1, with the ratio of sVEGFR1 : VEGF within tumor tissue and in plasma correlating with prognosis, although the exact underlying mechanisms remain unknown [15, 16].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation